Legal & General Group Plc Sells 4,995 Shares of Repligen Corporation $RGEN

Legal & General Group Plc lowered its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 6.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,803 shares of the biotechnology company’s stock after selling 4,995 shares during the quarter. Legal & General Group Plc’s holdings in Repligen were worth $12,913,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. raised its position in shares of Repligen by 120.6% in the fourth quarter. Hantz Financial Services Inc. now owns 1,293 shares of the biotechnology company’s stock valued at $212,000 after purchasing an additional 707 shares during the period. Swedbank AB bought a new stake in shares of Repligen during the 4th quarter worth $4,146,000. Coldstream Capital Management Inc. grew its stake in Repligen by 5.3% in the 4th quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock valued at $326,000 after buying an additional 101 shares during the last quarter. Lisanti Capital Growth LLC acquired a new position in Repligen in the 4th quarter valued at $3,189,000. Finally, Americana Partners LLC bought a new position in Repligen in the 4th quarter worth $224,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on RGEN shares. Wolfe Research started coverage on shares of Repligen in a research report on Tuesday. They set an “outperform” rating and a $145.00 target price for the company. Wells Fargo & Company cut their price objective on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. KeyCorp reissued an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Roth Mkm started coverage on Repligen in a report on Friday, April 17th. They issued a “buy” rating and a $160.00 target price on the stock. Finally, Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $164.64.

Repligen Stock Performance

NASDAQ:RGEN opened at $121.13 on Wednesday. The firm’s 50-day moving average is $118.05 and its 200-day moving average is $139.53. The company has a market cap of $6.83 billion, a price-to-earnings ratio of 134.59, a PEG ratio of 2.37 and a beta of 1.09. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter last year, the company earned $0.39 earnings per share. The firm’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities research analysts anticipate that Repligen Corporation will post 1.99 earnings per share for the current year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.